Skip to main content

Table 11 Test 4: Sensitivity Analysis Olanzapine Versus Risperidone: Changing CATIE Relapse Risk Ratios to Achieve Desired ICER Result

From: Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

 

ICER

RIS/OLZ Ratio

OLZ

RIS

1.55 (Base Case)*

Dominant

-

1.54

Cost-Neutral

0.70

Effectiveness-Neutral

  1. *Base case ratio from CATIE Phase 1 [23] which reported hospitalization risk ratios normalized to 1 person year of exposure: RIS = 0.45, OLZ = 0.29, and RIS/OLZ = 1.55.
  2. ICER = incremental cost-effectiveness ratio; RIS = risperidone; OLZ = olanzapine
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us